Iturralde TP

Language: Spanish
References: 11
Page: 129-132
PDF size: 98.63 Kb.

ABSTRACT

All patients with coronary heart disease (CHD) are at risk for sudden cardiac death (SCD) multiple factors in addition to reduced ejection fraction (EF) have been demonstrated to contribute to the risk for SCD after myocardial infarction (HI), these include the presence of non sustained ventricular tachycardia (NSVT), symptomatic heart failure (HF), and sustained monomorphic VT inducible by EP testing. The only specific antiarrhythmic treatment proved consistently is effective to reduce risk of SCD and total mortality is the ICD. ICD therapy is indicated to reduce the risk of SCD in 2 patient groups; patients whose LVEF is less than or equal to 35% as a result of prior MI and who have spontaneous NSVT and sustained monomorphic VT inducible by EP testing, and patients of and MI than occurred greated than or equal to 40 days earlier when HF (NYHA) functional class II or III symptoms) is present. Amiodarone therapy has been thought to be relatively safe in patients with prior MI who had symptomatic arrhythmias that required suppression. Although randomized trials have not demonstrated a survival benefit when empiric amiodarone is initiated early after MI, mortality was not increased, and arrhythmic deaths showed a consistent trend toward reduction with amiodarone treatment.

REFERENCES

1. Bayés de Luna A, Guindo SJ: Muerte súbita cardíaca, ed. Doyma, Barcelona, 1990.

2. Bayés de Luna A, Coumel PH, Leclercq JF: Ambulatory sudden death: Mechanism of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151-160.

3. Gold R: Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: Lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol 2000; 23(11): 1981-5.

4. Myerburg RJ: Scientific gaps in the prediction and prevention of suden cardiac death. J Cardiovasc Electrophysiol 2002; 13: 709-723.

5. Buxton AE, Lee KL, Fisher JD, et al: For the Multicenter Unsustained Tachycardia Investigator. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 34: 1882.

6. Moss AJ, Zareba W, Hall WJ, et al: Prophylatic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877.

7. Strickberger S, Hummel J, Barthlet T: Amiodarone vs implantable cardioverter defibrillator. Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic non-sustained ventricular tachycardia AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707-1712.

8. Bardy G: Sudden cardiac death in heart failure trial (SCD-HeFT). ACC New Orleans, Highlights 2004.

9. Kadish A, Quigg R, Schaechter A: Defibrillator in non ischemic cardiomyopathy treatment evaluation. PACE 2000; 23: 338-343.

10. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. JACC 2006; 48-5: 247-346.

11. Zipes D, Wellens HJJ: Sudden cardiac death. Circulation 1998; 98: 2334-2351.